Sandoz unveiled a direct-to-consumer platform starting with a single growth disorder medication, signaling the generic business’s push to reduce out-of-pocket costs for some patients. The initiative adopts a system used by several brand-name manufacturers to streamline patient access and affordability. The launch positions Sandoz to engage patients directly in care journeys rather than relying solely on prescriber-mediated pathways, potentially improving reach for chronic therapies where adherence and affordability can determine outcomes.